ADP-ribosylation signalling and human disease. Issue 4 (17th April 2019)

• Record Type: Journal Article
• Authors: Palazzo, Luca; Mikolčević, Petra; Mikoč, Andreja; Ahel, Ivan
• Is Part Of: Open biology. Volume 9:Issue 4(2019)
• Publication Date: 2019-04-17
• Subjects: ADP-ribosylation -- signalling -- translational medicine; Biology -- Periodicals; 570
• DOI: 10.1098/rsob.190041
• Languages: English
• ISSNs: 2046-2441

Abstract

Abstract : Abstract : ADP-ribosylation (ADPr) is a reversible post-translational modification of proteins, which controls major cellular and biological processes, including DNA damage repair, cell proliferation and differentiation, metabolism, stress and immune responses. In order to maintain the cellular homeostasis, diverse ADP-ribosyl transferases and hydrolases are involved in the fine-tuning of ADPr systems. The control of ADPr network is vital, and dysregulation of enzymes involved in the regulation of ADPr signalling has been linked to a number of inherited and acquired human diseases, such as several neurological disorders and in cancer. Conversely, the therapeutic manipulation of ADPr has been shown to ameliorate several disorders in both human and animal models. These include cardiovascular, inflammatory, autoimmune and neurological disorders. Herein, we summarize the recent findings in the field of ADPr, which support the impact of this modification in human pathophysiology and highlight the curative potential of targeting ADPr for translational and molecular medicine.